Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

IO Biotech doses first patient in Phase I/II IO102 and Keytruda trial

Predominant squamous cell carcinoma with a small focus of small cell carcinoma along the right edge. Credit: Yale Rosen.

Go Top